A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
Latest Information Update: 18 Jan 2024
At a glance
- Drugs Dordaviprone (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 12 Jan 2024 Status changed from suspended to discontinued.
- 06 Sep 2022 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.
- 11 Jul 2022 Planned End Date changed from 1 Jun 2023 to 1 Aug 2023.